Anke Biological (300009.SZ) signs an exclusive agency framework agreement for PA3-17 injection, the world's first autologous CAR-T cell therapy product targeting CD7 approved for clinical trials.

ChinastocksAPP news, Anke Biology (300009.SZ) announced that, in order to promote the sales and promotion of the PA3-17 injection product under its joint venture company Boshengji Medical Technology (Suzhou) Co., Ltd. (hereinafter referred to as "Boshengji Company"), the company has reached a strategic cooperation agreement with Boshengji Company. On November 11, 2025, they signed the "Exclusive Agency Framework Agreement for CD7-CAR-T (PA3-17 injection) and other products", stipulating the exclusive agency matters in the Greater China region (Mainland China, Hong Kong, Macao, and Taiwan) after the listing of the PA3-17 injection product.